1. Home
  2. SFWL vs BMEA Comparison

SFWL vs BMEA Comparison

Compare SFWL & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shengfeng Development Limited

SFWL

Shengfeng Development Limited

N/A

Current Price

$0.90

Market Cap

77.6M

Sector

Industrials

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.34

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFWL
BMEA
Founded
2001
2017
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.6M
90.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SFWL
BMEA
Price
$0.90
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
2.5K
989.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.87
52 Week High
$1.29
$3.08

Technical Indicators

Market Signals
Indicator
SFWL
BMEA
Relative Strength Index (RSI) 48.05 52.41
Support Level $0.88 $1.24
Resistance Level $1.02 $1.41
Average True Range (ATR) 0.04 0.10
MACD 0.00 0.02
Stochastic Oscillator 45.45 54.72

Price Performance

Historical Comparison
SFWL
BMEA

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: